- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01811316
A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Cambridge, Massachusetts, Estados Unidos, 02142
- The Forsyth Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Willing and able to read, understand and sign an Informed Consent form.
- Good general health as evidenced by the medical history.
- Between 18 and 65 years of age.
- Male or female.
- Minimum of 20 teeth, excluding crowns and third molar teeth.
- Mean whole mouth Modified Gingival Index of greater-than or equal to 2.0 at baseline.
- Willing to abstain from all oral hygiene procedures for 12-18 hours prior to clinical visits.
- Willing to abstain from eating and drinking in the morning of visits, only drinking water is allowed.
- Willing to abstain from interdental cleaning, chewing gums, oral whitening, mouth rinse and tobacco products for the study duration.
- Able to understand and follow study directions.
- No known history of allergy to dairy products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.
Exclusion Criteria
- Presence of orthodontic appliances.
- Intra-oral soft tissue lesions due to pathology or trauma
- Patients with aggressive periodontitis, acute necrotizing ulcerative gingivitis, or gross decay at discretion of PI.
- More than two sites with pocket depth >5mm and concomitant attachment loss of >2mm.
- Pregnant or lactating females or females of child bearing potential not using acceptable methods of birth control (hormonal, barriers or abstinence).
- Use of antibiotics within 3 months of enrollment
- History of drug use that is associated with gum overgrowth (i.e., Dilantin, nifedipine, etc)
- Chronic use of medication such as steroids, NSAIDs (more than 2-3 days/week), anti-coagulant medications, immunosuppressant medications or any other medications that in the opinion of the Investigator would interfere with the evaluation or confound interpretation of the study results. Use of low dose of acetylsalicylic acid (81 mg) is permitted.
- Unwilling to sign a confidentiality statement and/or return the test products.
- Medical condition which requires pre-medication prior to dental visits/procedures.
- Immune compromised individuals (HIV, AIDS, immunosuppressive drug therapy).
- Current use of probiotics or probiotic containing food (i.e., yogurt)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Probiotics Lozenge (twice a day)
Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
|
|
|
Comparador activo: Probiotics Lozenge (once a day)
Subjects take their lozenge once a day, one lozenge at night after brushing.
|
|
|
Comparador de placebos: Placebo Lozenge (once a day)
Subjects take their lozenge once a day, one lozenge at night after brushing.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Modified Gingival Index (MGI)
Periodo de tiempo: 4, 12 and 24 weeks
|
Modified Gingival Index (MGI) (Lobene, Weatherford et al. 1986) was measured on six gingival areas of all scorable teeth, using a scale of 0-4 as follows: Scores Criteria 0 Normal (absence of inflammation)
Whole mouth MGI scores were calculated by summing all scores and dividing by the number of examined scorable sites. |
4, 12 and 24 weeks
|
|
Change From Baseline in Bleeding on Probing (BOP)
Periodo de tiempo: 4, 12 and 24 weeks
|
Bleeding on probing was assessed 30 seconds after probing.
A dichotomous scoring system was used at six sites per tooth using one (1) and zero (0) for presence or absence, respectively.
BOP (%) is a percentage of sites BOP.
|
4, 12 and 24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Plaque Index (PI)
Periodo de tiempo: 4, 12 and 24 weeks
|
Plaque Index of Turesky Modification of Quigley-Hein (Turesky, Gilmore et al. 1970) (PI) was scored on all natural teeth (except third molars) after disclosing with erythrosine solution. Scores Criteria: 0 No plaque
|
4, 12 and 24 weeks
|
|
Change From Baseline in Probing Depth (PD)
Periodo de tiempo: 4, 12 and 24 weeks
|
Periodontal pocket depth (PD) was determined with a periodontal probe at six sites per tooth rounded to the next lower whole mm.
|
4, 12 and 24 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Inflammatory Markers in Gingival Crevicular
Periodo de tiempo: 15 days, 4, 12 and 24 weeks
|
Gingival Crevicular Fluid (GCF) samples will be analyzed for inflammatory cytokines/chemokines and matrix metalloproteases using multiplexing ELISA.
|
15 days, 4, 12 and 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hatice Hasturk, DDS, PhD, The Forsyth Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CLP-2013-1-23
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .